Search hospitals > California > Los Angeles
Cedars-Sinai Medical Center
Claim this profileLos Angeles, California 90048
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Tumors
Conducts research for Lymphoma
Conducts research for Solid Tumors
1450 reported clinical trials
172 medical researchers
Summary
Cedars-Sinai Medical Center is a medical facility located in Los Angeles, California. This center is recognized for care of Cancer, Breast Cancer, Tumors, Lymphoma, Solid Tumors and other specialties. Cedars-Sinai Medical Center is involved with conducting 1,450 clinical trials across 1,320 conditions. There are 172 research doctors associated with this hospital, such as Leo Mascarenhas, MD, Fataneh (Fae) Majlessipour, Raj Makkar, and Monica Mita, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Leo Mascarenhas, MDChildren's Hospital Los Angeles3 years of reported clinical research
Expert in Tumors
Studies Leukemia
48 reported clinical trials
108 drugs studied
Fataneh (Fae) MajlessipourCedars Sinai Medical Center6 years of reported clinical research
Expert in Tumors
Studies Brain Tumor
27 reported clinical trials
69 drugs studied
Raj MakkarCedars-Sinai Medical Center5 years of reported clinical research
Studies Mitral Valve Regurgitation
Studies Aortic Valve Stenosis
22 reported clinical trials
34 drugs studied
Monica Mita, MDCedars-Sinai Medical Center7 years of reported clinical research
Expert in Breast Cancer
Studies Solid Tumors
22 reported clinical trials
37 drugs studied
Clinical Trials running at Cedars-Sinai Medical Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Crohn's Disease
Parkinson's Disease
Brain Tumor
Prostate Cancer
Lymphoma
Acute Lymphoblastic Leukemia
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Ivermectin + Balstilimab
for Breast Cancer
This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as balstilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ivermectin may help block the formation of growths that may become cancer. Giving ivermectin with balstilimab may increase the effect of balstilimab in shrinking tumors in patients with triple negative breast cancer. The secondary objectives of the study include evaluating the following efficacy outcomes: objective response rate (ORR), progression free survival (PFS), overall survival (OS), duration of response (DOR), clinical benefit rate (CBR), and patients' quality of life (QOL) by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).
Recruiting2 awards Phase 1 & 214 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Cedars-Sinai Medical Center?
Cedars-Sinai Medical Center is a medical facility located in Los Angeles, California. This center is recognized for care of Cancer, Breast Cancer, Tumors, Lymphoma, Solid Tumors and other specialties. Cedars-Sinai Medical Center is involved with conducting 1,450 clinical trials across 1,320 conditions. There are 172 research doctors associated with this hospital, such as Leo Mascarenhas, MD, Fataneh (Fae) Majlessipour, Raj Makkar, and Monica Mita, MD.
Where is Cedars-Sinai Medical Center located?
**Cedars-Sinai Medical Center**
- **Address:** 8700 Beverly Blvd, Los Angeles, CA 90048
- **Directions:** Take the I-10 E or I-10 W to exit 7B for La Cienega Blvd. Head north on La Cienega Blvd and turn right onto Beverly Blvd.
Who should I call to ask about financial aid or insurance network?
**Cedars-Sinai Medical Center Contact Information:**
- **Patient Financial Services:**
- General Inquiries: (323) 866-8600
- Billing and Insurance Inquiries: 866-803-1777 (Monday through Friday, 8 am - 4:30 pm PT)
- **Patient Financial Advocates:**
- For Admitted Patients: 310-423-5071
For financial assistance, please visit our website at [cedars-sinai.org/billing-insurance/help-paying-your-bill.html](cedars-sinai.org/billing-insurance/help-paying-your-bill.html) to access the necessary resources.
What insurance does Cedars-Sinai Medical Center accept?
Cedars-Sinai Medical Center accepts more than 100 insurance plans, including private insurance, HMOs, and PPOs. They have contracts with Blue Cross PPO, Vivity HMO, and Blue Cross HMO, which may necessitate PCP selection and referrals for specific services. Additionally, they provide resources for individuals looking to purchase health insurance independently, with Blue Shield PPO covering their medical center and physicians.
What awards or recognition has Cedars-Sinai Medical Center received?
Cedars-Sinai Medical Center, located in Los Angeles, California, is celebrated for its exceptional medical care, having won the NRC Health's Consumer Choice Award for 20 consecutive years. It stands as a premier center for biomedical research, ranking among the top non-university hospitals in the US for competitive research funding from the National Institutes of Health.